NCT01959685View on ClinicalTrials.gov

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
PharmacokineticsTolerability
Interventions
DRUG

Androxal

125 mg Androxal, 250 mg Androxal separated by at least 7 days

DRUG

Placebo

Placebo, single dose

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Miami

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01959685 - A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal | Biotech Hunter | Biotech Hunter